Buy Abbott Laboratories - The Market Is Overestimating the Risk of Infant Formula Litigation

Buy Abbott Laboratories - The Market Is Overestimating the Risk of Infant Formula Litigation

CNBC

Abbott shares began its slide Friday after a jury ordered Reckitt Benckiser to pay $60 million to a plaintiff whose premature baby died of necrotizing enterocolitis, also known as NEC. In this example, the market looked at Abbott's roughly 1,000 pending lawsuits and multiplied it by the $60 million payout to one plaintiff — who was seeking a smaller figure of $25 million. There are a few key things to know from this statement: First, there is no scientific

#HEALTH #English #RO
Read more at CNBC